Watching safety of durvalumab with or without olaparib in endometrial cancer patients
Studies durvalumab, alone or with olaparib, in endometrial cancer patients receiving routine care.
Plain-language title generated from the registry record
Registry title: Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- SeoulSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06995833
- Record updated
- 2 September 2026
- Original description
Objectives of this study are to assess the safety and effectiveness of Durvalumab with or without Olaparib (hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug under the approved indication in Korea.Read full original descriptionShow less
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Objectives of this study are to assess the safety and effectiveness of Durvalumab with or without Olaparib (hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug under the approved indication in Korea.
This is a multicenter, prospective, observational, real world treatment study. Patients treated as part of routine practice at Korean healthcare centers by investigators will be identified and considered for inclusion in the study. The period of this study is expected to run for 4 years from the approval date of the indication for this study. Approximately 50 patients are expected to be enrolled during the study.
Patient will be followed for approximately 12 months from the first dose or up to 90 days after treatment discontinuation if the study drug is administered for less than 12 months, unless they withdraw consent, are lost to follow-up or death.
Inclusion: Patients eligible for the study drug according to the approved label in Korea; Provision of a signed and dated written informed consent by the patient or their legally acceptable representative.
Exclusion: Participation in any concurrent interventional trials during the period of the study drug treatment; Other off-label indications according to the approved label in Korea.